The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.
How did I get here: Calliditas Therapeutics’ Andy Udell
Udell cuts a unique figure within the world of pharma leadership for a bunch of reasons. Here, he talks pandemic takeaways and a life lesson gleaned from Tommy Boy.